Corxel Pharmaceuticals closed a $287 million Series D to push its oral small‑molecule GLP‑1 agonist CX‑11 through U.S. and planned global Phase II trials and begin Phase III preparations. The funding will also support Corxel’s broader cardiometabolic pipeline and global development activities. The capital raise signals continued investor appetite for oral incretin candidates and small‑molecule alternatives to injectable biologics. Corxel will use proceeds to accelerate enrollment and regulatory planning as competition in the obesity and diabetes drug class intensifies.